Precision BioSciences has received permission for a patent from the US Patent and Trademark Office. The patent application is titled “Engineered Meganucleases That Target Human Mitochondrial Genomes”. It covers a mitochondria-targeted ARCUS nuclease (mitoARCUS) that can target and eliminate certain mutant mitochondrial DNA. The company has also revealed PBGENE-PMM, a candidate for treatment of primary mitochondrial myopathy associated with this type of mutated mitochondrial DNA, using the mitoARCUS nuclease.
Just days before its data might be leaked, Qantas Airways obtained a permanent injunction
In July, DataBreaches reported that Qantas had obtained a preliminary injunction prohibiting the publication of any customer data stolen from it in a cyberattack by
